Beclomethasone dipropionate in pediatric perennial extrinsic rhinitis.
A double-blind, crossover trial of beclomethasone dipropionate intranasal aerosol was undertaken in 30 children suffering from long-term perennial extrinsic rhinitis refractive to conventional therapy with a success rate of 83%. There were no side effects. Maximum improvement was a seen a week after initiation of the active drug. Nasal blockage and rhinorrhoea were most responsive. It is suggested the beclomethasone dipropionate is an effective and safe treatment of children suffering from extrinsic perennial rhinitis.
D000293:Adolescent; D001507:Beclomethasone / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D013997:Time Factors
D001507:Beclomethasone